Bibliografía del artículo
1. MM Gertler, SM Garn and SA Levine, Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med. 34 (1951), pp. 1421-1431.2. C Iribarren, DS Sharp, JD Curb and K Yano, High uric acid: A metabolic marker of coronary heart disease among alcohol abstainers. J Clin Epidemiol. 49 (1996), pp. 673-678.3. W Rathmann, H Hauner, K Dannehl and FA Gries, Association of elevated uric acid with coronary heart disease in diabetes mellitus. Diabete Metab. 19 (1993), pp. 159-166.4. H Vuorinen-Markkola and H Yki-Järvinen, Hyperuricemia and Insulin Resistance. J Clin Endocrinol Metab. 78 (1994), pp. 25-29.5. F Facchini, Y-D Ida Chen, CB Hollenbeck and GM Reaven, Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 266 (1991), pp. 3008-3011.6. AQ Galvan, A Natali, S Baldi, S Frascerra, G Sanna, D Ciociaro and E Ferrannini, Effect of insulin on uric acid excretion in humans. Am J Physiol. 268 (1995), pp. E1-E5.7. GM Reaven, H Lithell and L Landsberg, Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 334 (1996), pp. 374-381.8. Tinahones FJ, Collantes E, Perez Lindón G, C-Soriguer FJ, Lillo JA, Sánchez Guijo P. Decreased triglyceride levels with low-calorie diet and increased renal excretion of uric acid in hyperuricemic-hyperlipidemic patients. An Rheum Dis 1995; 54:609-610.9. Tinahones FJ, Collantes E, Gonzalez A, C-Soriguer F, Añón J and Sánchez P. Increased VLDL levels and disminished renal excretion of uric acid in hyperuricemic-hypertrigliceridemic patients.Br J Rheumatol 1995; 34:920-924.10. Tinahones FJ, Pérez-Lindón G, Soriguer FJ, Pareja A, Sánchez-Guijo P, Collantes E. Dietary alterations of plasma VLDL levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metabolism 1997; 82:1188-1191.11. Martine Groenendijk, Rita M. Cantor, Tjerk W. A. De Bruin, and Geesje M. Dallinga-Thie. New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia J. Lipid Res. 2001 42:188-194.12. Dawn M. Waterworth, Josep Ribalta, Viviane Nicaud, Jean Dallongeville, Steve E. Humphries, and Philippa Talmud ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance Tests Circulation 99 (14):1872-1877.13. Ferns GAA, Ritchie C, Stocks J, Galton DJ Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet 1985; 2:300-303.14. Ordovás JM, Civeira F, Genest JJ, Robbins AH, Meade T, Pocovi M et al Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III and A-IV gene locus: relationships with lipids, apolipoproteins and premature coronary artery disease. Atherosclerosis 1991; 87:75-86.15. Xu CF, Angelico F, Del Ben M, Humphries SE Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo A-I levels in boys and girls. Genet Epidemiol 1993; 10:113-122.16. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994; 35:1292-1296.17. Civeira F, Pocovi M, Cenarro A, Garcés C, Ordovás JM Adenine for guanine substitution. 78 base pairs to the apolipoprotein (apo) A-I gene: relation with high density lipoprotein cholesterol and apo A-I concentrations. Clin Genet 1993; 44:307-312.18. Soriguer-Escofet F, Esteva I, Rojo-Martinez G, Ruiz de Adana S, Catala M, Merelo MJ, Aguilar M, Tinahones F, Garcia-Almeida JM, Gomez-Zumaquero JM, Cuesta-Munoz AL, Ortego J, Freire JM; Diabets Group of the Andalusian Society of Endocrinology and Nutrtion. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002 Jun;56(3):213-20.19. Shoulders CC, Narcisi TM, Jarmuz A, Brett DJ, Bayliss JD, Scott J. Characterization of genetic markers in the 5'flanking region of the apo A1 gene. Hum Genet. 1993 Mar; 91(2):197-8.20. Jeenah M, Kessling A, Miller N, Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med. 1990 Jun;7(3):233-41.21. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3-UTR polymorphisms. Proc Natl Acad Sci USA 1993; 90:4562–6.